Core Viewpoint - Anke Biotech (300009.SZ) is strengthening its strategic position in the innovative drug sector by increasing its investment in its affiliate, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. [1] Group 1: Investment Details - The company plans to invest 30 million RMB of its own funds to increase its stake in Boshengji by subscribing to the newly registered capital of 119,062 RMB [1] - After the completion of this capital increase, the company will hold a 21.4121% equity stake in Boshengji [1]